Glucosamine Sulfate Suppresses the Expression of Matrix Metalloproteinase-3 in Osteosarcoma Cells in Vitro

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2016 Aug 27

PMID 27562075

Citations 5

Authors

Florian Pohlig

Jorg Ulrich

Ulrich Lenze

Heinrich M L Muhlhofer

Norbert Harrasser

Christian Suren

Johannes Schauwecker

Philipp Mayer-Kuckuk

Rudiger von Eisenhart-Rothe

Affiliations

Soon will be listed here.

Abstract

Background: Glucosamine, a common dietary supplement, has a possible anti-sarcoma effect. However, an understanding of the underlying mechanism of such an effect is limited. For this study we hypothesized that glucosamine suppresses the basal level of matrix metalloproteinase expression in human osteosarcoma cell lines.

Methods: We examined the osteosarcoma cell lines, MG-63 and SaOS-2. Cells were exposed to 0, 10, 50 and 100 μg/ml glucosamine sulfate for 48 h and treatment toxicity was determined through measurement of cell viability and proliferation. Relative gene expression of matrix metalloproteinase (MMP)-2, -3 and -9 was quantified by real-time polymerase chain reaction. Protein levels of MMP-2 and -9 were assessed by ELISA.

Results: Administration of 10, 50 or 100 μg/ml glucosamine sulfate had no effect on the cell viability of MG-63 and SaOS-2 cells. A significant reduction of MMP expression in both cell lines was observed only for MMP-3, while a decrease in MMP-9 was seen in SaOS-2 cells. The expression of MMP-2 was not significantly affected in either cell line. Protein level of MMP-3 was reduced in both cell lines upon stimulation with 10 μg/ml glucosamine sulfate whereas for MMP-9 a decrease could only be observed in SaOS-2 cells.

Conclusion: In this study, we found a pronounced suppressive effect of glucosamine sulfate particularly on MMP-3 and also MMP-9 mRNA and protein levels in osteosarcoma cell lines in vitro. The data warrants further investigations into the potential anti-tumor efficacy of glucosamine sulfate in osteosarcoma.

Citing Articles

Association between glucosamine use and cancer mortality: A large prospective cohort study.

Zhou J, Wu Z, Lin Z, Wang W, Wan R, Liu T Front Nutr. 2022; 9:947818.

PMID: 36407521 PMC: 9667031. DOI: 10.3389/fnut.2022.947818.

Impact of health and lifestyle food supplements on periodontal tissues and health.

Spahr A, Divnic-Resnik T Periodontol 2000. 2022; 90(1):146-175.

PMID: 35916868 PMC: 9804634. DOI: 10.1111/prd.12455.

MicroRNA-Based Diagnosis and Treatment of Metastatic Human Osteosarcoma.

Sasaki R, Osaki M, Okada F Cancers (Basel). 2019; 11(4).

PMID: 31003401 PMC: 6521107. DOI: 10.3390/cancers11040553.

Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.

Li S, Cao Y, Li L, Zhang H, Lu X, Bo C PLoS One. 2019; 14(4):e0214857.

PMID: 30947317 PMC: 6448860. DOI: 10.1371/journal.pone.0214857.

CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.

Tang Q, Lu J, Zou C, Shao Y, Chen Y, Narala S Oncogene. 2018; 37(27):3617-3630.

PMID: 29610525 DOI: 10.1038/s41388-018-0231-2.

References

Seccareccia E, Pinard M, Wang N, Li S, Burnier J, Dankort D . The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis. Oncogenesis. 2014; 3:e116. PMC: 5189963. DOI: 10.1038/oncsis.2014.28. View

Zucker S, Cao J . Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?. Cancer Biol Ther. 2009; 8(24):2371-3. PMC: 2829367. DOI: 10.4161/cbt.8.24.10353. View

Deryugina E, Quigley J . Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25(1):9-34. DOI: 10.1007/s10555-006-7886-9. View

Zeng Z, Huang Y, Cohen A, Guillem J . Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996; 14(12):3133-40. DOI: 10.1200/JCO.1996.14.12.3133. View

Jaffe N . Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 2010; 152:239-62. DOI: 10.1007/978-1-4419-0284-9_12. View

Gervasi D, Raz A, Dehem M, Yang M, Kurkinen M, Fridman R . Carbohydrate-mediated regulation of matrix metalloproteinase-2 activation in normal human fibroblasts and fibrosarcoma cells. Biochem Biophys Res Commun. 1996; 228(2):530-8. DOI: 10.1006/bbrc.1996.1694. View

Qato D, Alexander G, Conti R, Johnson M, Schumm P, Lindau S . Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008; 300(24):2867-78. PMC: 2702513. DOI: 10.1001/jama.2008.892. View

Scotto dAbusco A, Calamia V, Cicione C, Grigolo B, Politi L, Scandurra R . Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. Arthritis Res Ther. 2007; 9(5):R104. PMC: 2212570. DOI: 10.1186/ar2307. View

Zachara N, Hart G . O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim Biophys Acta. 2004; 1673(1-2):13-28. DOI: 10.1016/j.bbagen.2004.03.016. View

10.

Tsai H, Su H, Huang C, Fong Y, Hsu C, Tang C . CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget. 2014; 5(11):3800-12. PMC: 4116521. DOI: 10.18632/oncotarget.1998. View

11.

Biggee B, Blinn C, McAlindon T, Nuite M, Silbert J . Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2005; 65(2):222-6. PMC: 1798018. DOI: 10.1136/ard.2005.036368. View

12.

Ahmad A, Li Y, Sarkar F . The bounty of nature for changing the cancer landscape. Mol Nutr Food Res. 2016; 60(6):1251-63. DOI: 10.1002/mnfr.201500867. View

13.

Overall C, Kleifeld O . Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6(3):227-39. DOI: 10.1038/nrc1821. View

14.

Molnar Z, BEKESI J . Cytotoxic effects of D-glucosamine on the ultrastructures of normal and neoplastic tissues in vivo. Cancer Res. 1972; 32(4):756-65. View

15.

Molnar Z, BEKESI J . Effects of D-glucosamine, D-mannosamine, and 2-deoxy-D-glucose on the ultrastructure of ascites tumor cells in vitro. Cancer Res. 1972; 32(2):380-9. View

16.

Bell G, Kantor E, Lampe J, Shen D, White E . Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012; 27(8):593-603. PMC: 3557824. DOI: 10.1007/s10654-012-9714-6. View

17.

QUASTEL J, Cantero A . Inhibition of tumour growth by D-glucosamine. Nature. 1953; 171(4345):252-4. DOI: 10.1038/171252a0. View

18.

Mendis E, Kim M, Rajapakse N, Kim S . The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. Bioorg Med Chem Lett. 2009; 19(10):2755-9. DOI: 10.1016/j.bmcl.2009.03.126. View

19.

Zachara N, Hart G . Cell signaling, the essential role of O-GlcNAc!. Biochim Biophys Acta. 2006; 1761(5-6):599-617. DOI: 10.1016/j.bbalip.2006.04.007. View

20.

Chesnokov V, Gong B, Sun C, Itakura K . Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation. Cancer Cell Int. 2014; 14:45. PMC: 4057579. DOI: 10.1186/1475-2867-14-45. View